A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)


Study Number:


Principal Investigator:


Barrett Cancer Center; University Hospital; University Pointe


This study will see if AMG 595 is safe when given to adult men and women and whether it causes any side effects.  This study will also look at what doses of  AMG 595 are safe for people to take and evaluate the amount of AMG 595 in your blood at various times during the study. The purpose of this study is to find out more about AMG 595 in people with cancer. AMG 595 is still experimental and is not approved by any regulatory health agency (like the Food and Drug Administration [FDA] or European Medicines Agency [EMA]) for use in people with cancer. It is anticipated that you will be in this study for about 7.5 months depending on how you are tolerating and responding to treatment with AMG 595.  This includes a 14-day screening period when tests and assessments will be done to determine if you can participate in this study, about 6 months of treatment and a follow up visit about 1 month after your last dose of AMG 595. When you have completed treatment, long-term follow up will continue approximately every 4 months until 12 months after the last person was enrolled in the study.   About twenty (20) people will take part in this research study at the University of Cincinnati.  Up to 60 subjects are expected to enroll in the study at various institutions.

Qualified participants must be at least 18 and have recurrent malignant glioma (brain cancer).

For more information, please contact Alison Kastl, BS, CCRC, Director of Clinical Trials, at kastla@ucmail.uc.edu or (513) 584-0436.

This entry was posted in . Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Print This Page
  • Make an Appointment: Schedule Now
  • Sign up for our newsletter!
  • Hope Stories

    • Jerry’s Story: Spinal Tumor

      Jerry's Story: Spinal Tumor On an ordinary day in February 2009, John M. Tew, MD, got one of the true surprises of his career. He was seeing patients in his Mayfield Clinic office on the University of Cincinnati medical campus when an unexpected guest...
    • Lynne’s Story: Brain Metastasis

      Lynne's Story: Brain MetastasisSemiretired and working part-time at a restaurant, Lynne knew something was amiss when she looked at the cash register and then struggled to make her hands produce the correct amount of change. Could she have suffered a stroke? Lynne pushed the...
    • Bob’s Story: Recurrent Glioblastoma

      Bob's Story: Recurrent Glioblastoma Glioblastomas come back. Sometimes sooner, sometimes later, but they always come back. “That’s the...
    • Jim’s Story: Acromegaly / Pituitary Tumor

      Jim's Story: Acromegaly / Pituitary Tumor Four years later, Jim’s story just keeps getting better. Because four years after being treated for a pituitary tumor at the UC Brain Tumor Center, Jim continues to feel better and better. The size of his head has gone down....
    • Troy’s Testimonial: ‘Out of 5 Stars, They Get 6’

      Troy’s Testimonial: ‘Out of 5 Stars, They Get 6’ Troy Sheldon has something to say, and he’d like...
    • Troy’s Story: Proton Therapy for Brain Cancer

      Troy's Story: Proton Therapy for Brain Cancer Troy Witt, 65, a London, Kentucky resident and a self-proclaimed "country boy,” says he loves his family, fishing, woodworking and riding on his tractor. But all of these activities have been put on hold since spring 2016 when Witt’s...
    • Brian’s Story: Meningioma

      Brian's Story: Meningioma “Carefree” is the word Brian uses to describe his life back then. He was 39 years old, happily married and the father of three children under the age of 5. “Life was busy, but that felt normal,” he says, reflecting. “The only...